These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36851155)

  • 1. The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies.
    Leśniak M; Lipniarska J; Majka P; Kopyt W; Lejman M; Zawitkowska J
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
    Frega G; Wu Q; Le Naour J; Vacchelli E; Galluzzi L; Kroemer G; Kepp O
    Oncoimmunology; 2020 Jul; 9(1):1796002. PubMed ID: 32934889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01.
    Wilkinson A; Lattmann E; Roces CB; Pedersen GK; Christensen D; Perrie Y
    J Control Release; 2018 Dec; 291():1-10. PubMed ID: 30291987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.
    Sun H; Li Y; Zhang P; Xing H; Zhao S; Song Y; Wan D; Yu J
    Biomark Res; 2022 Dec; 10(1):89. PubMed ID: 36476317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptors and their role in hematologic malignancies.
    Wolska A; Lech-Maranda E; Robak T
    Curr Mol Med; 2009 Apr; 9(3):324-35. PubMed ID: 19355914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio
    Keppler M; Straß S; Geiger S; Fischer T; Späth N; Weinstein T; Schwamborn A; Guezguez J; Guse JH; Laufer S; Burnet M
    Front Immunol; 2023; 14():1168252. PubMed ID: 37409123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toll-like receptor 8 agonists improve NK-cell function primarily targeting CD56
    Veneziani I; Alicata C; Pelosi A; Landolina N; Ricci B; D'Oria V; Fagotti A; Scambia G; Moretta L; Maggi E
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor Activity of Toll-Like Receptor 7 Agonists.
    Chi H; Li C; Zhao FS; Zhang L; Ng TB; Jin G; Sha O
    Front Pharmacol; 2017; 8():304. PubMed ID: 28620298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
    Serrano R; Wesch D; Kabelitz D
    Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
    Smits EL; Ponsaerts P; Berneman ZN; Van Tendeloo VF
    Oncologist; 2008 Aug; 13(8):859-75. PubMed ID: 18701762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Latest Approach of Immunotherapy with Endosomal TLR Agonists Improving NK Cell Function: An Overview.
    Veneziani I; Alicata C; Moretta L; Maggi E
    Biomedicines; 2022 Dec; 11(1):. PubMed ID: 36672572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of viral single-stranded RNA by Toll-like receptors.
    Diebold SS
    Adv Drug Deliv Rev; 2008 Apr; 60(7):813-23. PubMed ID: 18241955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
    Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
    Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule Toll-like receptor 7 agonists localize to the MHC class II loading compartment of human plasmacytoid dendritic cells.
    Russo C; Cornella-Taracido I; Galli-Stampino L; Jain R; Harrington E; Isome Y; Tavarini S; Sammicheli C; Nuti S; Mbow ML; Valiante NM; Tallarico J; De Gregorio E; Soldaini E
    Blood; 2011 May; 117(21):5683-91. PubMed ID: 21487111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.
    Hunt JR; Kleindl PA; Moulder KR; Prisinzano TE; Forrest ML
    Bioorg Med Chem Lett; 2020 Jan; 30(2):126788. PubMed ID: 31784317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
    Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
    Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
    Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
    Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod.
    Zhu J; Lai K; Brownile R; Babiuk LA; Mutwiri GK
    Mol Immunol; 2008 Jun; 45(11):3238-43. PubMed ID: 18439678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toll-like receptor agonists in cancer therapy.
    Adams S
    Immunotherapy; 2009 Nov; 1(6):949-64. PubMed ID: 20563267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.